VIR logo

Vir Biotechnology (VIR) Cash From Investing

Annual CFI

$164.63 M
+$1.36 B+113.79%

31 December 2023

VIR Cash From Investing Chart

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Quarterly CFI

$118.60 M
-$93.00 M-43.95%

30 September 2024

VIR Quarterly CFI Chart

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

TTM CFI

$253.82 M
+$177.56 M+232.82%

30 September 2024

VIR TTM CFI Chart

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

VIR Cash From Investing Performance

PeriodPeriodAnnualAnnualQuarterlyQuarterlyTTMTTM
1 y1 year-+213.2%+54.2%
3 y3 years+216.9%+131.4%+280.3%
5 y5 years+164.3%+260.8%+199.1%

VIR Cash From Investing High & Low

PeriodPeriodAnnual vs highAnnual vs highAnnual vs lowAnnual vs lowQuarter. vs highQuarter. vs highQuarter. vs lowQuarter. vs lowTTM vs highTTM vs highTTM vs lowTTM vs low
3 y3 yearsat high+113.8%-48.5%+117.9%at high+117.9%
5 y5 yearsat high+113.8%-48.5%+117.9%-14.7%+117.9%
alltimeall timeat high+113.8%-48.5%+117.9%-14.7%+117.9%

Vir Biotechnology Cash From Investing History

DateAnnualQuarterlyTTM
Sept 2024
-
$118.60 M(-44.0%)
$253.82 M(+232.8%)
June 2024
-
$211.61 M(+644.6%)
$76.26 M(-19.7%)
Mar 2024
-
$28.42 M(-127.1%)
$94.97 M(-42.3%)
Dec 2023
$164.63 M(-113.8%)
-$104.81 M(+77.8%)
$164.63 M(+41.5%)
Sept 2023
-
-$58.95 M(-125.6%)
$116.31 M(-123.9%)
June 2023
-
$230.31 M(+134.8%)
-$487.35 M(-50.8%)
Mar 2023
-
$98.08 M(-164.0%)
-$989.99 M(-17.0%)
Dec 2022
-$1.19 B(+747.5%)
-$153.13 M(-76.9%)
-$1.19 B(-15.8%)
Sept 2022
-
-$662.61 M(+143.3%)
-$1.42 B(+108.1%)
June 2022
-
-$272.33 M(+158.4%)
-$681.44 M(+104.2%)
Mar 2022
-
-$105.39 M(-72.1%)
-$333.74 M(+137.0%)
Dec 2021
-$140.81 M
-$377.58 M(-611.2%)
-$140.81 M(-147.3%)
DateAnnualQuarterlyTTM
Sept 2021
-
$73.86 M(-2.0%)
$297.48 M(+677.9%)
June 2021
-
$75.38 M(-13.9%)
$38.24 M(-244.1%)
Mar 2021
-
$87.53 M(+44.2%)
-$26.55 M(+169.2%)
Dec 2020
-$9.86 M(-96.2%)
$60.71 M(-132.8%)
-$9.86 M(-93.2%)
Sept 2020
-
-$185.38 M(-1851.3%)
-$144.34 M(-263.4%)
June 2020
-
$10.59 M(-89.8%)
$88.33 M(-27.7%)
Mar 2020
-
$104.22 M(-241.3%)
$122.22 M(-147.7%)
Dec 2019
-$256.16 M(+323.8%)
-$73.77 M(-256.0%)
-$256.16 M(+40.4%)
Sept 2019
-
$47.29 M(+6.3%)
-$182.39 M(-20.6%)
June 2019
-
$44.48 M(-116.2%)
-$229.68 M(-16.2%)
Mar 2019
-
-$274.16 M
-$274.16 M
Dec 2018
-$60.44 M(+101.5%)
-
-
Dec 2017
-$29.99 M
-
-

FAQ

  • What is Vir Biotechnology annual cash flow from investing activities?
  • What is the all time high annual CFI for Vir Biotechnology?
  • What is Vir Biotechnology quarterly cash flow from investing activities?
  • What is the all time high quarterly CFI for Vir Biotechnology?
  • What is Vir Biotechnology quarterly CFI year-on-year change?
  • What is Vir Biotechnology TTM cash flow from investing activities?
  • What is the all time high TTM CFI for Vir Biotechnology?
  • What is Vir Biotechnology TTM CFI year-on-year change?

What is Vir Biotechnology annual cash flow from investing activities?

The current annual CFI of VIR is $164.63 M

What is the all time high annual CFI for Vir Biotechnology?

Vir Biotechnology all-time high annual cash flow from investing activities is $164.63 M

What is Vir Biotechnology quarterly cash flow from investing activities?

The current quarterly CFI of VIR is $118.60 M

What is the all time high quarterly CFI for Vir Biotechnology?

Vir Biotechnology all-time high quarterly cash flow from investing activities is $230.31 M

What is Vir Biotechnology quarterly CFI year-on-year change?

Over the past year, VIR quarterly cash flow from investing activities has changed by +$223.41 M (+213.16%)

What is Vir Biotechnology TTM cash flow from investing activities?

The current TTM CFI of VIR is $253.82 M

What is the all time high TTM CFI for Vir Biotechnology?

Vir Biotechnology all-time high TTM cash flow from investing activities is $297.48 M

What is Vir Biotechnology TTM CFI year-on-year change?

Over the past year, VIR TTM cash flow from investing activities has changed by +$89.19 M (+54.18%)